Biohaven Ltd.

12/16/2024 | Press release | Distributed by Public on 12/16/2024 06:31

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.